Restoring expression of tumour suppressor PTEN by engineered circular RNA-enhanced Osimertinib sensitivity in non-small cell lung cancer

Haoran Li; Zheng Liu; Shaoyi Chen; Jingsheng Cai; Peiyu Wang; Kezhong Chen; Mantang Qiu

doi:10.1002/ctm2.1792

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (8) : e1792 DOI: 10.1002/ctm2.1792

LETTER TO THE JOURNAL

Restoring expression of tumour suppressor PTEN by engineered circular RNA-enhanced Osimertinib sensitivity in non-small cell lung cancer

Haoran Li ¹^,²^,³
, Zheng Liu ¹^,²^,³
, Shaoyi Chen ¹^,²^,³
, Jingsheng Cai ¹^,²^,³
, Peiyu Wang ¹^,²^,³
, Kezhong Chen ¹^,²^,³
, Mantang Qiu ¹^,²^,³^,^†

Author information +

History +

PDF

Cite this article

Download citation ▾

Haoran Li, Zheng Liu, Shaoyi Chen, Jingsheng Cai, Peiyu Wang, Kezhong Chen, Mantang Qiu. Restoring expression of tumour suppressor PTEN by engineered circular RNA-enhanced Osimertinib sensitivity in non-small cell lung cancer. Clinical and Translational Medicine, 2024, 14(8): e1792 DOI:10.1002/ctm2.1792

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Obi P, Chen YG. The design and synthesis of circular RNAs. Methods. 2021;196:85-103.

[2]	Wesselhoeft RA, Kowalski PS, Anderson DG. Engineering circular RNA for potent and stable translation in eukaryotic cells. Nat Commun. 2018;9(1):2629.

[3]	Wesselhoeft RA, Kowalski PS, Parker-Hale FC, Huang Y, Bisaria N, Anderson DG. RNA circularization diminishes immunogenicity and can extend translation duration in vivo. Mol Cell. 2019;74(3):508-520. e4.

[4]	Shinde SR, Maddika S. PTEN modulates EGFR late endocytic trafficking and degradation by dephosphorylating Rab7. Nat Commun. 2016;7:10689.

[5]	Jin G, Kim MJ, Jeon HS, et al. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer. 2010;69(3):279-283.

[6]	Nussinov R, Tsai CJ, Jang H. Anticancer drug resistance: an update and perspective. Drug Resist Updat. 2021;59:100796.

[7]	Wang Z, Feng Y, Song J, Sun D, Zhang YY. Function, drug resistance and prognostic effect of AKR1C2 in human cancer. Neoplasma. 2023;70(3):319-332.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.